Impact of ranolazine on exercise tolerance and arrhythmias in patients with INOCA

Authors

DOI:

https://doi.org/10.15587/2519-4798.2021.241534

Keywords:

coronary heart disease, INOCA, ranolazine, stress test

Abstract

The aim of the study to evaluate the effect of supplementation of basic therapy by ranolazine in patients with INOCA on exercise test parameters and Holter ECG monitoring.

Materials and methods. 53 patients with stable coronary heart disease were examined, including 18 men (33.9 %) and 35 (66 %) women, the average age of patients was 57 (±9.68) years. According to the results of coronary angiography all patients had non-obstructive coronary arteries. In addition to physical and laboratory examination, bicycle ergometry, Holter ECG monitoring and echocardiography were included in the examination of patients. Patients were divided into 2 groups: group I - patients who in addition to standard therapy received ranolazine at a dose of 1000 mg twice a day for 6 months, and group II patients with standard coronary heart disease therapy. After 6 months from the beginning of the observation an objective examination, echocardiography, exercise test, Holter ECG monitoring were repeated.

Results. The study found that patients receiving ranolazine in addition to standard therapy had a statistically significant increase in exercise duration after 6 months compared with baseline and group II. Before treatment in group I, the duration of the exercise test was 356.51±180.24s, and after treatment 414.32±142.10s (p=0.03). In group II, the duration of the test before treatment was 361.4±160.24 c, and after 380.5±152.2 s (p=0.15). It was also found that the duration of the test differed significantly in group I after treatment of patients from group II after treatment of patients with a standard treatment regimen (p=0.04). According to the results of Holter ECG monitoring in group I found a positive effect of ranolazine on the frequency of ventricular arrhythmias: before treatment n=1142 [30; 2012], after treatment n=729 [23; 1420], while in group II a significant difference between the number of extrasystoles before treatment and after not detected (n=1026 [17; 1920], n=985 [15; 1680], respectively) p=0.18.

Conclusions. The addition of ranolazine to the basic therapy of patients with non-obstructive coronary arteries disease helps to increase exercise tolerance (according to the loading stress test) and contributes to a significant reduction in the number of ventricular arrhythmias (according to Holter-ECG) compared with both baseline and group II

Author Biographies

Vira Tseluyko, V. N. Karazin Kharkiv National University

Doctor of Medical Sciences, Professor, Head of Department, Honored Scientist and of Technology of Ukraine

Department of Cardiology

Tetyana Pylova, Kharkiv Medical Academy of Postgraduate Education

Postgraduate Student

Department of Cardiology and Functional Diagnostics

References

Ma, J., Chen, X. (2021). Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes. Frontiers in Cardiovascular Medicine, 7. doi: http://doi.org/10.3389/fcvm.2020.631398

Douglas, P. S., Hoffmann, U., Patel, M. R., Mark, D. B., Al-Khalidi, H. R., Cavanaugh, B. et. al. (2015). Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease. New England Journal of Medicine, 372 (14), 1291–1300. doi: http://doi.org/10.1056/nejmoa1415516

Camici, P. G., Crea, F. (2007). Coronary Microvascular Dysfunction. New England Journal of Medicine, 356 (8), 830–840. doi: http://doi.org/10.1056/nejmra061889

Kaski, J.-C., Crea, F., Gersh, B. J., Camici, P. G. (2018). Reappraisal of Ischemic Heart Disease. Circulation, 138 (14), 1463–1480. doi: http://doi.org/10.1161/circulationaha.118.031373

Nishi, T., Murai, T., Ciccarelli, G., Shah, S. V., Kobayashi, Y., Derimay, F. et. al. (2019). Prognostic Value of Coronary Microvascular Function Measured Immediately After Percutaneous Coronary Intervention in Stable Coronary Artery Disease. Circulation: Cardiovascular Interventions, 12 (9). doi: http://doi.org/10.1161/circinterventions.119.007889

Agewall, S., Beltrame, J. F., Reynolds, H. R., Niessner, A., Rosano, G., Caforio, A. L. P. et. al. (2016). ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. European Heart Journal, 38, 143–153. doi: http://doi.org/10.1093/eurheartj/ehw149

Rayner‐Hartley, E., Sedlak, T. (2016). Ranolazine: A Contemporary Review. Journal of the American Heart Association, 5 (3). doi: http://doi.org/10.1161/jaha.116.003196

Zhu, H., Xu, X., Fang, X., Zheng, J., Zhao, Q., Chen, T., Huang, J. (2019). Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials. Clinical Therapeutics, 41 (10), 2137–2152.e12. doi: http://doi.org/10.1016/j.clinthera.2019.08.008

Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C. et. al. (2019). 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 41 (3), 407–477. doi: http://doi.org/10.1093/eurheartj/ehz425

Inobe, Y., Kugiyama, K., Morita, E., Kawano, H., Okumura, K., Tomiguchi, S. et. al. (1996). Role of Adenosine in Pathogenesis of Syndrome X: Assessment With Coronary Hemodynamic Measurements and Thallium-201 Myocardial Single-Photon Emission Computed Tomography. Journal of the American College of Cardiology, 28 (4), 890–896. doi: http://doi.org/10.1016/s0735-1097(96)00271-9

Zharinov, O., Ivanov, Yu., Kitch, V. (Eds.) (2021). Funktsionalna diahnostyka. Kyiv: Chetverta khvylia, 784.

Zharinov, O. J., Kitch, V. O., Thor, N. V. (2006). Navantazhuvalni proby v kardiolohii. Kyiv: Medytsyna svitu, 89.

Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy «Stabilna ishemichna khvoroba sertsia» (2016). Nakaz Ministerstva okhorony zdorovia Ukrainy No. 152. 02.03.2016. Available at: https://neuronews.com.ua/ru/files/1865170518.pdf

Kofler, T., Hess, S., Moccetti, F., Pepine, C. J., Attinger, A., Wolfrum, M. et. al. (2021). Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction – A Systematic Review and Meta-analysis of Randomized Trials. CJC Open, 3 (1), 101–108. doi: http://doi.org/10.1016/j.cjco.2020.09.005

Chaitman, B. R., Skettino, S. L., Parker, J. O., Hanley, P., Meluzin, J., Kuch, J. et. al. (2004). Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. Journal of the American College of Cardiology, 43 (8), 1375–1382. doi: http://doi.org/10.1016/j.jacc.2003.11.045

Bairey Merz, C. N., Handberg, E. M., Shufelt, C. L., Mehta, P. K., Minissian, M. B., Wei, J. et. al. (2015). A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. European Heart Journal, 37 (19), 1504–1513. doi: http://doi.org/10.1093/eurheartj/ehv647

Zhu, H., Xu, X., Fang, X., Zheng, J., Zhao, Q., Chen, T., Huang, J. (2019). Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials. Clinical Therapeutics, 41 (10), 2137–2152.e12. doi: http://doi.org/10.1016/j.clinthera.2019.08.008

Aguilar, J., Wei, J., Quesada, O., Shufelt, C., Bairey Merz, C. N. (2021). Coronary Microvascular Dysfunction. Sex Differences in Cardiac Diseases. Elsevier, 141–158. doi: http://doi.org/10.1016/b978-0-12-819369-3.00021-6

Curnis, A., Salghetti, F., Cerini, M., Vizzardi, E., Sciatti, E., Vassanelli, F. et. al. (2017). Ranolazine therapy in drug-refractory ventricular arrhythmias. Journal of Cardiovascular Medicine, 18 (7), 534–538. doi: http://doi.org/10.2459/jcm.0000000000000521

Shah, N. R., Cheezum, M. K., Veeranna, V., Horgan, S. J., Taqueti, V. R., Murthy, V. L. et. al. (2017). Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. Journal of the American Heart Association, 6 (5). doi: http://doi.org/10.1161/jaha.116.005027

Downloads

Published

2021-09-30

How to Cite

Tseluyko, V., & Pylova, T. (2021). Impact of ranolazine on exercise tolerance and arrhythmias in patients with INOCA. ScienceRise: Medical Science, (5(44), 10–15. https://doi.org/10.15587/2519-4798.2021.241534

Issue

Section

Medical Science